Scholarlink

Background <p>Surgical site infections (SSIs) in aesthetic surgery, though rare (~1%), can compromise outcomes. Standard preoperative antiseptics such as chlorhexidine gluconate (CHG) and povidone-iodine are effective but may cause irritation or toxicity. Clinisept+ is a stabilised hypochlorous acid (HOCl) solution with broad antimicrobial activity and excellent tissue compatibility, yet evidence for its surgical use is limited.</p> Methods <p>A prospective, multicentre audit was conducted in four UK private aesthetic surgery clinics (January–August 2024). All patients received Clinisept+ as the sole preoperative skin preparation. Demographics, smoking status, procedure type, antibiotic prophylaxis, SSIs, wound complications, and skin reactions were recorded. SSIs were defined as infections requiring treatment. Associations with smoking and antibiotic use were analysed with Fisher’s exact test.</p> Results <p>A total of 157 patients (median age 45 years; 78% female) underwent diverse aesthetic procedures. The SSI rate was 1.27% (2/157), both minor and resolving with oral antibiotics. All SSIs occurred in smokers without prophylactic antibiotics (<i>p</i> = 0.04 vs non-smokers). Wound-healing complications occurred in 5.1% (8/157), none infected. No skin sensitivity or allergic reactions were reported.</p> Conclusions <p>Clinisept+ yielded SSI rates comparable to historical data for CHG and povidone-iodine, with excellent tolerability and no observed skin irritation. HOCl-based preparation may be advantageous in patients with sensitive skin or when operating near mucosal or delicate regions. These findings support its safe use in aesthetic surgery, though randomised controlled trials are warranted to confirm non-inferiority.</p> Level of Evidence V <p>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rethinking Skin Preparation: Is Hypochlorous Acid (Clinisept+) a Safe Alternative Skin Preparation in Aesthetic Surgery?

  • 期刊论文

  • 发表日期：

    2026年4月20日

查看全文
  • Ali Arnaout,
  • Mohammad R. Goodarzi,
  • Nora F. Nugent,
  • Marc D. Pacifico,
  • Fulvio Urso-Baiarda,
  • Charles A. T. Durrant,
  • Simon Heppell,
  • Ahmed S. Ali-Khan

摘要

Background

Surgical site infections (SSIs) in aesthetic surgery, though rare (~1%), can compromise outcomes. Standard preoperative antiseptics such as chlorhexidine gluconate (CHG) and povidone-iodine are effective but may cause irritation or toxicity. Clinisept+ is a stabilised hypochlorous acid (HOCl) solution with broad antimicrobial activity and excellent tissue compatibility, yet evidence for its surgical use is limited.

Methods

A prospective, multicentre audit was conducted in four UK private aesthetic surgery clinics (January–August 2024). All patients received Clinisept+ as the sole preoperative skin preparation. Demographics, smoking status, procedure type, antibiotic prophylaxis, SSIs, wound complications, and skin reactions were recorded. SSIs were defined as infections requiring treatment. Associations with smoking and antibiotic use were analysed with Fisher’s exact test.

Results

A total of 157 patients (median age 45 years; 78% female) underwent diverse aesthetic procedures. The SSI rate was 1.27% (2/157), both minor and resolving with oral antibiotics. All SSIs occurred in smokers without prophylactic antibiotics (p = 0.04 vs non-smokers). Wound-healing complications occurred in 5.1% (8/157), none infected. No skin sensitivity or allergic reactions were reported.

Conclusions

Clinisept+ yielded SSI rates comparable to historical data for CHG and povidone-iodine, with excellent tolerability and no observed skin irritation. HOCl-based preparation may be advantageous in patients with sensitive skin or when operating near mucosal or delicate regions. These findings support its safe use in aesthetic surgery, though randomised controlled trials are warranted to confirm non-inferiority.

Level of Evidence V

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.